CagriSema is a cagrilintide + semaglutide blend. Eloralintide is a copy of amylin.
The difference is reach: Eloralintide acts on 1 receptor and CagriSema acts on 2 receptors. More receptors has generally meant more effect, and more side effects.
| Comparison | CagriSema cagrilintide and semaglutide · Cagrilintide + Semaglutide | Eloralintide LY3841136 |
|---|---|---|
| How it works | How it works CagriSema is two drugs in one weekly injection: cagrilintide and semaglutide, at fixed doses. The logic is that two separate fullness pathways should add up. | How it works Eloralintide is an amylin receptor agonist designed with tolerability as the main goal. |
| What it is | A weekly two-in-one shot combining cagrilintide and semaglutide for bigger loss. | An experimental weekly fullness-hormone shot for weight loss. |
| Status | In trialsInvestigational | In trialsInvestigational |
| Typical dose | 2.4 mg per week | 1–9 mg per week |
| How often | Weekly | Weekly |
| Stays active | 6 to 8 days for both parts | 14 to 16 days |
| Dose comes from | Clinical trial protocol | Clinical trial protocol |
| Cycled? | Not cycled in the trials Clinical trial protocol | Not cycled in the trials Clinical trial protocol |
| What it does | ||
| Drug class | Cagrilintide + semaglutide blend | Amylin agonist |
| Used for | A weekly two-in-one shot combining an appetite-lowering peptide with semaglutide, for bigger weight loss than either alone. | An experimental weekly shot that copies a natural fullness hormone for weight loss, positioned as easy to tolerate. |
| Receptors hit | GLP-1, amylin | amylin |
| Numbers | ||
| Full dose line | 2.4 mg per week | 1 up to 9 mg per week (trial doses) |
| Why that cycle | Given continuously for the whole study period: REDEFINE 1, 68 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. | Given continuously for the whole study period: 48 weeks in phase 2, 75 to 80 weeks in phase 3. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | 37 residues |
| Common vial | 10 mg | 10 mg |
| Before you start | ||
| Route | Under the skin (subcutaneous) | Under the skin (subcutaneous) |
| Do not use if | A personal or family history of medullary thyroid cancer, or MEN 2 Pregnancy | No formal contraindications established Pregnancy |
What people actually report
CagriSema
- Stomach side effects.
- The dose is increased slowly from a low start, and it is not yet approved.
- Severe stomach pain that spreads to your back
- A lump or swelling in your neck, hoarseness, or trouble swallowing
Eloralintide
- Stomach side effects.
- Trial-only.
- Vomiting badly enough that you cannot keep fluids down
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.